Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter of 2018 after the market close on Wednesday, November 7, 2018.
October 31, 2018
· 2 min read